Novel Regimen Boosts PFS in Relapsed/Refractory Myeloma

]]>(MedPage Today) -- ORLANDO--An immunomodulator-free regimen including the anti-CD38 agent daratumumab (Darzalex) significantly improved progression-free survival (PFS) in relapsed/refractory multiple myeloma, initial results from a randomized...